TLSI Earnings — TriSalus Life Sciences, Inc. Common Stock Post-ER Performance | BigEarnings
TLSI — TriSalus Life Sciences, Inc. Common Stock
XNAS · Healthcare · Medical Devices
Price$3.41
Market Cap$209.4M
P/E—
52W Range$2.20 – $7.95
Next Earnings2026-08-11
About TriSalus Life Sciences, Inc. Common Stock
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
